Our Services
Medical Information
Helpful Resources
Published on: 7/21/2026
Doctors monitor kidney health in patients taking Ozempic (semaglutide) using five key tests: estimated glomerular filtration rate (eGFR), serum creatinine, urinary albumin-to-creatinine ratio (UACR), blood urea nitrogen (BUN), and blood pressure. Together, these markers detect early kidney changes and help evaluate Ozempic's protective benefits.
Key findings: Clinical trials show Ozempic patients experience slower eGFR decline and reduced albuminuria compared to placebo, suggesting meaningful kidney protection.
What affects your results: Blood sugar control, hydration status, diet, and concurrent medications all influence kidney test interpretation. Details on monitoring schedules, result interpretation, lifestyle tips, and when to contact your provider are below.
If you're experiencing symptoms or unsure whether your kidney health is on track with Ozempic, don't wait for your next appointment to get clarity. A free, instant, online symptom check can help you understand what your body may be signaling, identify potential red flags, and guide your next steps—whether that's a conversation with your doctor or reassurance that things look normal. It takes just a few minutes and could give you the confidence to act early.
Reviewed for medical accuracy: 07/21/2026
Doctor's Note: How Your Doctor Measures Kidney Protection on Ozempic
Ozempic (semaglutide) is a medication commonly prescribed for type 2 diabetes. Beyond blood sugar control, clinical trials have shown that GLP-1 receptor agonists like Ozempic can have benefits for kidney health. Your doctor will use a series of standard kidney function tests to track how well your kidneys are doing—and to spot early signs of any trouble.
Your physician will combine lab tests with your medical history, blood sugar readings, blood pressure, and overall health to gauge the protective effects of Ozempic on your kidneys.
Estimated Glomerular Filtration Rate (eGFR)
Serum Creatinine
Urinary Albumin-to-Creatinine Ratio (UACR)
Blood Urea Nitrogen (BUN)
Blood Pressure Monitoring
Your doctor's exact plan may vary, but here's a common approach when starting or adjusting Ozempic:
| Time Point | Tests |
|---|---|
| Baseline (pre-Ozempic) | eGFR, serum creatinine, UACR, BUN, blood pressure |
| 3 months after start | eGFR, serum creatinine, UACR, blood pressure |
| Every 6 months thereafter | eGFR, UACR, blood pressure |
| Annually | Full renal panel + assessment of other risk factors (lipids, eye exam, foot exam) |
If any test results change significantly, your doctor may:
Your doctor will always interpret results in the context of your overall health, medications, diet, and lifestyle.
Contact your healthcare provider if you experience:
If you're noticing any concerning symptoms and want to better understand whether they could be related to kidney issues, use this free Chronic Kidney Disease symptom checker to help determine if you should seek more urgent evaluation.
Monitoring kidney function tests while on Ozempic helps your doctor ensure you're not only managing blood sugar but also protecting your most vital filtering organs. Early detection of changes means interventions can be made sooner—often slowing or halting further damage.
Always speak to your doctor about any test results or symptoms you find concerning. If you ever experience something that feels life-threatening or very serious, seek medical attention right away.
Your kidneys are worth protecting. With the right tests, regular follow-up, and partnership between you and your healthcare team, Ozempic can be one part of a comprehensive plan to keep your kidneys healthy for years to come.
(References)
* Perkovic V, et al. Semaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease. N Engl J Med. 2024 May 23;390(21):1982-1994. doi: 10.1056/NEJMoa2403983. PMID: 38676231.
* Mann JFE, et al. Kidney Outcomes With Semaglutide in People With Type 2 Diabetes and CKD: A Prespecified Secondary Analysis of the SUSTAIN 6 Trial. Kidney Int Rep. 2021 Mar;6(3):601-610. doi: 10.1016/j.ekir.2020.12.029. PMID: 33738419.
* Cai X, et al. Effects of GLP-1 receptor agonists on kidney outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2021 Oct 21;106(11):e4407-e4419. doi: 10.1210/clinem/dgab456. PMID: 34185121.
* Sun B, et al. Effects of Semaglutide on Renal Function in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes Ther. 2021 Sep;12(9):2439-2453. doi: 10.1007/s13300-021-01111-9. PMID: 34327763.
* Nauck MA, et al. Renal effects of GLP-1 receptor agonists: current evidence and future perspectives. Lancet Diabetes Endocrinol. 2022 Jul;10(7):510-526. doi: 10.1016/S2213-8587(22)00092-2. PMID: 35716501.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.